Volume : 13, Issue : 08, August – 2026

Title:

PENTOXIFYLLINE SUSTAINED-RELEASE MATRIX TABLETS: FORMULATION STRATEGIES, RELEASE MECHANISMS AND RECENT ADVANCES

Authors :

Tejal Nandan Pawar, Dr. S. S. Angadi, Reshma Patil, Dr. Vandana Patil

Abstract :

Sustained-release matrix tablets are an essential strategy for prolonging medication release, reducing dose frequency, and enhancing patient compliance. Pentoxifylline, a hemorheologic agent with a short biological half-life, is a potential candidate for sustained-release administration. This review focuses on the formulation strategies, polymers, release mechanisms, and assessment of Pentoxifylline sustained-release matrix tablets. Hydrophilic polymers, particularly hydroxypropyl methylcellulose (HPMC), play a crucial role in modulating drug release through hydration, gel formation, diffusion, swelling, and erosion. Different production processes, including direct compression, wet granulation, and dry granulation, can be applied based on the formulation needs. Evaluation comprises pre-compression and post-compression properties, dissolution testing, release kinetics, and stability assessment. Mathematical models such as Zero-order, First-order, Higuchi, and Korsmeyer–Peppas models assist explain drug-release behaviour. Overall, HPMC-based matrix technologies provide a promising and feasible platform for regulated oral delivery of Pentoxifylline.
Keywords: Pentoxifylline, Sustained-release, Matrix tablets, HPMC K4M, Drug release, Diffusion, Swelling, Release kinetics.

Cite This Article:

Please cite this article in press Tejal N Pawar et al., Pentoxifylline Sustained-Release Matrix Tablets: Formulation Strategies, Release Mechanisms And Recent Advances. Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4(6):297-307.
2. Raz I, Ben-David J, Hussein Z, Samara E. Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1988;26(4):206-208.
3. Jayakar B, Margret C, Bhowmik D, Sampath Kumar KP. Formulation and evaluation of extended release tablets of Pentoxifylline. Int J Pharm Res Technol. 2010;2(2):81-85.
4. Thube MW, Shahi SR, Gulecha BS, Tadvee I, Zadbuke N, Somani VG. Formulation, development and evaluation of extended release tablet of Pentoxifylline. Int J Pharm Res Dev. 2009;1:1-7.
5. Hussain AH, Khalil YI. Some variables affecting the formulation of Pentoxifylline as a solid sustained release dosage form. Iraqi J Pharm Sci. 2008;17(1):1-6.
6. Sripal Reddy M, Krishniah YSR, Ram Rao T, Satyanarayana S. Dissolution studies on Pentoxifylline sustained release tablets: influences of storage. Indian J Pharm Sci. [Publication details as reported by source].
7. Comparative in vitro dissolution and in vivo bioequivalence of two Pentoxifylline sustained release formulations. Drug Res. 2012.
8. Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2020;10:CD005262.
9. Indian Pharmacopoeia Commission. Pentoxifylline prolonged-release tablets. Indian Pharmacopoeia. Ghaziabad: Indian Pharmacopoeia Commission; 2018.
10. Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. Bioimpacts. 2012;2(4):175-187.
11. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Adv Drug Deliv Rev. 1993;11(1-2):37-57.
12. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2-3):139-157.
13. Siepmann J, Podual K, Sriwongjanya M, Peppas NA, Bodmeier R. A new model describing the swelling and drug release kinetics from hydroxypropyl methylcellulose tablets. J Pharm Sci. 1999;88(1):65-72.
14. Ford JL. Design and evaluation of hydroxypropyl methylcellulose matrix tablets for oral controlled release. Drug Dev Ind Pharm. 1999;25(9):1085-1095.
15. Bettini R, Colombo P, Massimo G, Catellani PL, Vitali T. Swelling and drug release in hydrogel matrices: polymer viscosity and matrix porosity effects. Eur J Pharm Sci. 1994;2(3):213-219.
16. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release. 1996;39(2-3):231-237.
17. Colombo P, Bettini R, Massimo G, Catellani PL, Santi P, Peppas NA. Drug diffusion front movement is important in drug release control from swellable matrix tablets. J Pharm Sci. 1995;84(8):991-997.
18. Rekhi GS, Jambhekar SS, Ford JL. Effect of formulation factors on drug release from hydrophilic matrix tablets. J Pharm Pharmacol. 1999;51(8):1005-1013.
19. Nokhodchi A. An overview of the effect of formulation and processing variables on the release of drugs from hydrophilic matrices. J Pharm Pharm Sci. 2005;8(1):18-25.
20. Ghori MU, Conway BR. Hydrophilic matrices for oral control drug delivery. Am J Pharmacol Sci. 2015;3(5):103-109.
21. Khamanga SMM, Walker RB. Matrix tablets as drug delivery systems. Pharm Dev Technol. 2011;16(3):227-238.
22. Ju RTC, Nixon PR, Patel MV. Drug release from hydrophilic matrices. 1. New scaling laws for predicting polymer and drug release based on the polymer disentanglement concentration and the diffusion layer. J Pharm Sci. 1995;84(12):1455-1463.
23. Ju RTC, Nixon PR, Patel MV, Tong DM. Drug release from hydrophilic matrices. 2. A mathematical model based on the polymer disentanglement concentration and the diffusion layer. J Pharm Sci. 1995;84(12):1464-1477.
24. Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52(12):1145-1149.
25. Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011;418(1):6-12.
26. Ritger PL, Peppas NA. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987;5(1):23-36.
27. Ritger PL, Peppas NA. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J Control Release. 1987;5(1):37-42.
28. Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 1989;57(2):169-172.
29. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-223.
30. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-133.
31. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23(8):923-931.
32. United States Pharmacopeial Convention. United States Pharmacopeia 46–National Formulary 41. Rockville, MD: United States Pharmacopeial Convention; 2023.
33. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.

Volume : 13, Issue : 08, August – 2026

Title:

EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS

Authors :

Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan

Abstract :

Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.

Cite This Article:

Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.